MicroRNA expression profile of bromocriptine-resistant prolactinomas

Molecular and Cellular Endocrinology

Volumn 395, Issue 1-2, 2014, Pages 10-18

  Wu, Zhe Bao ^a,b   Li, Wei Qiang ^c   Lin, Shao Jian ^b   Wang, Cheng De ^b   Cai, Lin ^b   Lu, Jiang Long ^b   Chen, Yun Xiang ^d   Su, Zhi Peng ^b   Shang, Han Bing ^a   Yang, Wen Lei ^a   Zhao, Wei Guo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c Yuyao People's Hospital   (China)

^d Jinhua People's Hospital   (China)

Author keywords

Bromocriptine; MicroRNA; MicroRNA 93; p21; Prolactinoma; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; MICRORNA; MICRORNA 126; MICRORNA 136; MICRORNA 142; MICRORNA 144; MICRORNA 17; MICRORNA 22; MICRORNA 30A; MICRORNA 382; MICRORNA 451; MICRORNA 486; MICRORNA 92A; MICRORNA 93; PROTEIN P21; UNCLASSIFIED DRUG; HORMONE ANTAGONIST; RNA;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MALE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; UPREGULATION; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; BROMOCRIPTINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONE ANTAGONISTS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROLACTINOMA; RNA, NEOPLASM;

EID: 84905858626     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.07.014     Document Type: Article

References (57)

1. Amaral F.C., Torres N., Saggioro F., Neder L., Machado H.R., Silva W.A., et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J. Clin. Endocrinol. Metab 2009, 94:320-323.
2. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
4. Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.F., Dunning M.J., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8:R214.
5. Bottoni A., Piccin D., Tagliati F., Luchin A., Zatelli M.C., degli Uberti E.C. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J. Cell. Physiol 2005, 204:280-285.
6. Bottoni A., Zatelli M.C., Ferracin M., Tagliati F., Piccin D., Vignali C., et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J. Cell. Physiol 2007, 210:370-377.
7. Brue T., Pellegrini I., Gunz G., Morange I., Dewailly D., Brownell J., et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab 1992, 74:577-584.
8. Butz H., Liko I., Czirjak S., Igaz P., Khan M.M., Zivkovic V., et al. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J. Clin. Endocrinol. Metab 2010, 95:E181-E191.
9. Butz H., Liko I., Czirjak S., Igaz P., Korbonits M., Racz K., et al. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary 2011, 14:112-124.
10. Casanueva F.F., Molitch M.E., Schlechte J.A., Abs R., Bonert V., Bronstein M.D., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf) 2006, 65:265-273.
11. Catania A., Maira F., Skarmoutsou E., D'Amico F., Abounader R., Mazzarino M.C. Insight into the role of microRNAs in brain tumors (review). Int. J. Oncol 2012, 40:605-624.
12. Chen Y.H., Heneidi S., Lee J.M., Layman L.C., Stepp D.W., Gamboa G.M., et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes 2013, 62:2278-2286.
13. Colao A., Di Sarno A., Sarnacchiaro F., Ferone D., Di Renzo G., Merola B., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab 1997, 82:876-883.
14. Croce C.M., Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
15. Dai B., Meng J., Peyton M., Girard L., Bornmann W.G., Ji L., et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 2011, 71:3658-3668.
16. D'Angelo D., Palmieri D., Mussnich P., Roche M., Wierinckx A., Raverot G., et al. Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J. Clin. Endocrinol. Metab 2012, 97:E1128-E1138.
17. Di Sarno A., Landi M.L., Cappabianca P., Di Salle F., Rossi F.W., Pivonello R., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J. Clin. Endocrinol. Metab 2001, 86:5256-5261.
18. Ding Y., Wang Y., Chen J., Hu Y., Cao Z., Ren P., et al. p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Tumour Biol 2014, 35:3119-3123.
19. Du L., Schageman J.J., Subauste M.C., Saber B., Hammond S.M., Prudkin L., et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol. Cancer Res 2009, 7:1234-1243.
20. Fontana L., Fiori M.E., Albini S., Cifaldi L., Giovinazzi S., Forloni M., et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 2008, 3:e2236.
21. Fu X., Tian J., Zhang L., Chen Y., Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012, 586:1279-1286.
22. Gao W., Shen H., Liu L., Xu J., Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J. Cancer Res. Clin. Oncol 2011, 137:557-566.
23. Gentilin E., Tagliati F., Filieri C., Mole D., Minoia M., Rosaria Ambrosio M., et al. miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cdelta. Endocrinology 2013, 154:1690-1700.
24. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr. Rev 2006, 27:485-534.
25. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
26. Inomata M., Tagawa H., Guo Y.M., Kameoka Y., Takahashi N., Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009, 113:396-402.
27. Kaduthanam S., Gade S., Meister M., Brase J.C., Johannes M., Dienemann H., et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 2013, 80:223-227.
28. Kovacs K., Stefaneanu L., Horvath E., Buchfelder M., Fahlbusch R., Becker W. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J. Neurosurg 1995, 82:886-890.
29. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther 2008, 7:2152-2159.
30. Lin R.J., Xiao D.W., Liao L.D., Chen T., Xie Z.F., Huang W.Z., et al. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J. Surg. Oncol 2012, 105:175-182.
31. Ma M., Huang Y., Gong Z., Zhuang L., Li C., Yang H., et al. Discovery of DNA viruses in wild-caught mosquitoes using small RNA high throughput sequencing. PLoS ONE 2011, 6:e24758.
32. Mao Z.G., He D.S., Zhou J., Yao B., Xiao W.W., Chen C.H., et al. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn. Pathol 2010, 5:79.
33. Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 2005, 8:43-52.
34. Nair V.S., Maeda L.S., Ioannidis J.P. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J. Natl. Cancer Inst 2012, 104:528-540.
35. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res 2008, 14:2690-2695.
36. Neelakandan K., Babu P., Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr. Cancer Drug Targets 2012, 12:716-740.
37. Palumbo T., Faucz F.R., Azevedo M., Xekouki P., Iliopoulos D., Stratakis C.A. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 2013, 32:1651-1659.
38. Qian Z.R., Asa S.L., Siomi H., Siomi M.C., Yoshimoto K., Yamada S., et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod. Pathol 2009, 22:431-441.
39. Qin L.F., Ng I.O. Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 2001, 172:7-15.
40. Sarver A.L., Thayanithy V., Scott M.C., Cleton-Jansen A.M., Hogendoorn P.C., Modiano J.F., et al. MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet J. Rare Dis 2013, 8:7.
41. Stilling G., Sun Z., Zhang S., Jin L., Righi A., Kovacs G., et al. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 2010, 38:67-75.
42. Trivellin G., Butz H., Delhove J., Igreja S., Chahal H.S., Zivkovic V., et al. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am. J. Physiol. Endocrinol. Metab 2012, 303:E708-E719.
43. Wang C., Su Z., Sanai N., Xue X., Lu L., Chen Y., et al. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment. Oncol. Rep 2012, 27:1312-1320.
44. Wang X.S., Gong J.N., Yu J., Wang F., Zhang X.H., Yin X.L., et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012, 119:4992-5004.
45. Wu Z.B., Yu C.J., Su Z.P., Zhuge Q.C., Wu J.S., Zheng W.M. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J. Neurosurg 2006, 104:54-61.
46. Wu Z.B., Su Z.P., Wu J.S., Zheng W.M., Zhuge Q.C., Zhong M. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary 2008, 11:63-70.
47. Wu Z.B., Zheng W.M., Su Z.P., Chen Y., Wu J.S., Wang C.D., et al. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J. Neurooncol 2010, 99:25-32.
48. Wu Z.B., Cai L., Lin S.J., Lu J.L., Yao Y., Zhou L.F. The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. Brain Res 2013, 1529:16-25.
49. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
50. Yang I.P., Tsai H.L., Hou M.F., Chen K.C., Tsai P.C., Huang S.W., et al. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis 2012, 33:1522-1530.
51. Yang Y., Wu J., Guan H., Cai J., Fang L., Li J., et al. MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett 2012, 586:3608-3612.
52. Yi B., Piazza G.A., Su X., Xi Y. MicroRNA and cancer chemoprevention. Cancer Prev. Res. (Phila) 2013, 6:401-409.
53. Yu Y., Yang L., Zhao M., Zhu S., Kang R., Vernon P., et al. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 2012, 26:1752-1760.
54. Zhang H.H., Zhang Z.Y., Che C.L., Mei Y.F., Shi Y.Z. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines. Int. J. Clin. Exp. Pathol 2013, 6:1734-1746.
55. Zhu H., Wu H., Liu X., Evans B.R., Medina D.J., Liu C.G., et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol 2008, 76:582-588.
56. Ziller C., Lincet H., Muller C.D., Staedel C., Behr J.P., Poulain L. The cyclin-dependent kinase inhibitor p21(cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett 2004, 212:43-52.
57. Zou Z., Wu L., Ding H., Wang Y., Zhang Y., Chen X., et al. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J. Biol. Chem 2012, 287:4148-4156.